Introduction: Korea as a Global R&D Hub
The MFDS IND approval status is a critical barometer for pharmaceutical and biotech professionals planning research and development strategies. In June 2025, the Ministry of Food and Drug Safety (MFDS) approved 62 investigational new drug (IND) applications.
Among these, 44 approvals (about 71 %) were for foreign-developed products, while 18 (29 %) originated in Korea. Phase 3 trials accounted for 27 approvals, followed by 12 Phase 2 and 9 Phase 1 trials; the rest included Phase 3b, Phase 1/2, Phase 2/3, Phase 2a and 2b. Such numbers underscore Korea’s capability to support late-stage clinical studies. MFDS typically reviews INDs within 30 working days, and institutional review boards complete ethical reviews in roughly three weeks, making Korea a competitive destination compared with many Western countries. The nation’s well-developed hospital infrastructure and skilled healthcare workforce enable rapid patient recruitment.
Detailed Analysis: Phase and Regional Distribution
The high proportion of Phase 3 approvals highlights Korea’s capacity to conduct large-scale pivotal trials. Steady numbers of Phase 2 and Phase 1 approvals indicate a healthy early-stage pipeline. In terms of development region, 44 approvals were for foreign-developed drugs—more than double the domestic count—signalling that multinational companies view Korea as a strategic trial hub. Domestic development numbered 18 approvals, including innovative products such as autologous CD19‑targeted CAR‑T cells and herbal-based therapies, reflecting growing diversity and technological sophistication. To boost domestic numbers further, expanding government funding and facilitating technology transfer will be crucial.
Therapeutic Trends: Oncology, Immunology and Cardiovascular Disease
The June approvals reveal a strong focus on oncology. Numerous targeted therapies—including daratumumab, a claudin‑1 antibody–drug conjugate (ALE.P02) and JSB462 (luxdegalutamide)—were approved across phases. Oncolytic viruses like the recombinant vaccinia vector OTS‑412 and cell therapies such as CAR‑T cells also feature prominently. In immunology, risankizumab and vedolizumab were approved for inflammatory bowel diseases, while poseltinib entered trials for autoimmune disorders. Cardiovascular trials included antithrombotics (selatogrel), lipid-lowering agents and combinations targeting comorbid diabetes and hypertension. Neurological trials explored novel agents for Alzheimer’s disease (AL101, KarXT) and acute ischemic stroke (Neu2000KWL), addressing unmet medical needs.
Corporate and CRO Dynamics
Novartis Korea topped the list with six approvals, followed by AbbVie Korea with five. Global contract research organizations (CROs) like IQVIA Korea and Parexel Korea received four approvals each, underscoring the sophistication of Korea’s CRO ecosystem. CROs manage trial design, data management and patient recruitment on behalf of sponsors, working closely with local hospitals to ensure high-quality execution. Domestic players like Celltrion and Hanmi Pharmaceutical advanced antibody and small-molecule programs, while biotech start-ups such as Bichedam and Novomedicine pursued natural product-based therapies, enriching the innovation landscape.
Regulatory and Policy Developments
The MFDS is moving to shorten review timelines and adjust fee structures, enhancing predictability for sponsors and attracting more global investment. Regulatory guidelines for advanced therapies—including gene and cell therapies—are continuously updated, with stricter safety monitoring and long-term follow‑up requirements. Government initiatives through the Korea National Enterprise for Clinical Trials (KoNECT) provide training programs and data platforms, improving transparency and access to trial information. Digital transformation initiatives—such as electronic document submissions and centralized IRB processes—are expected to further enhance efficiency.
Collaboration and Future Challenges
While high foreign participation benefits Korea’s clinical trial industry, sustainable growth requires expanding domestic pipelines and internalizing technology. Building partnerships early in the drug development cycle, enhancing clinical data analytics and fostering regulatory expertise will help local companies compete globally. Ethical patient recruitment, public awareness and community engagement also remain important. Korea adheres to international quality standards, meeting the stringent requirements of global sponsors; maintaining and strengthening these standards will be key to future success.
Conclusion: Leveraging Insights and Looking Ahead
The June 2025 MFDS IND approvals reaffirm Korea’s ascent as a world-class clinical trial hub. A diverse array of indications and innovative therapies received approval, and collaboration between multinational and domestic companies is increasing. Stakeholders should analyze this data to refine R&D strategies, identify partnership opportunities and anticipate regulatory changes. Continuous monitoring of MFDS policies and active engagement with Korean partners will be essential for leveraging this dynamic landscape.
Request a Quote: We provide tailored support for clinical trial design, regulatory consulting and execution in Korea. [Request a proposal here] to work with experienced professionals who can guide you through every step.
Subscribe to Our Newsletter: Stay informed with the latest MFDS regulations, clinical trial trends and market analyses. [Subscribe to our newsletter] for curated content designed for domestic and international pharma & biotech professionals.